<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30362384</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>09</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1475-6374</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>34</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2019</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of enzyme inhibition and medicinal chemistry</Title>                <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.</ArticleTitle>            <Pagination>                <MedlinePgn>117-123</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2018.1532419</ELocationID>            <Abstract>                <AbstractText>Drug combination represents one of the most accredited strategies of cancer therapy able to improve drug efficacy and possibly overcome drug resistance. Among the agents used to complement conventional chemotherapy, carbonic anhydrase IX (CAIX) inhibitors appear as one of the most suitable, as markers of hypoxic and acidic cancer cells which do not respond to chemo- and radiotherapy. We performed preclinical in vitro assays to evaluate whether the SLC-0111 CAIX inhibitor co-operates and potentiates the cytotoxic effects of conventional chemotherapeutic drugs in A375-M6 melanoma cells, MCF7 breast cancer cells, and HCT116 colorectal cancer cells. Here, we demonstrate that the SLC-0111 CAIX inhibitor potentiates cytotoxicity of Dacarbazine and Temozolomide currently used for advanced melanoma treatment. SLC-0111 also increases breast cancer cell response to Doxorubicin and enhances 5-Fluorouracil cytostatic activity on colon cancer cells. These findings disclose the possibility to extend the use of CAIX inhibitors in the combination therapy of various cancer histotypes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Andreucci</LastName>                    <ForeName>Elena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ruzzolini</LastName>                    <ForeName>Jessica</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peppicelli</LastName>                    <ForeName>Silvia</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bianchini</LastName>                    <ForeName>Francesca</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Laurenzana</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carta</LastName>                    <ForeName>Fabrizio</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>b Department of NEUROFARBA , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Supuran</LastName>                    <ForeName>Claudiu T</ForeName>                    <Initials>CT</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4262-0323</Identifier>                    <AffiliationInfo>                        <Affiliation>b Department of NEUROFARBA , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Calorini</LastName>                    <ForeName>Lido</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Clinical and Experimental Biomedical Sciences &quot;Mario Serio&quot;, Section of Experimental Pathology and Oncology , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Center of Excellence for Research, Transfer and High Education DenoTHE , University of Florence , Florence , Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>            <NlmUniqueID>101150203</NlmUniqueID>            <ISSNLinking>1475-6366</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C000625353">SLC-0111</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>7GR28W0FJI</RegistryNumber>                <NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 4.2.1.1</RegistryNumber>                <NameOfSubstance UI="C089226">CA9 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 4.2.1.1</RegistryNumber>                <NameOfSubstance UI="D000071231">Carbonic Anhydrase IX</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>U3P01618RT</RegistryNumber>                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>YF1K15M17Y</RegistryNumber>                <NameOfSubstance UI="C047246">temozolomide</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2018 Jan 6;18(1):41</RefSource>                <PMID Version="1">29304770</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2016 Jul;37(7):9023-35</RefSource>                <PMID Version="1">26762407</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2006 Aug;5(8):2115-20</RefSource>                <PMID Version="1">16928833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 Jul 27;103(3):340-6</RefSource>                <PMID Version="1">20606684</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Exp Pharmacol Physiol. 2016 Aug;43(8):723-37</RefSource>                <PMID Version="1">27097837</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2017 Jan;6(1):288-297</RefSource>                <PMID Version="1">28028936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jan 17;8(3):3933-3945</RefSource>                <PMID Version="1">27965469</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2017 Nov 1;408:43-54</RefSource>                <PMID Version="1">28826720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2007 Sep;12(9):1114-23</RefSource>                <PMID Version="1">17914081</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2018 Feb;148:174-183</RefSource>                <PMID Version="1">29309757</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 May 25;102(11):1627-35</RefSource>                <PMID Version="1">20461082</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2017 Apr 9;8(7):1187-1196</RefSource>                <PMID Version="1">28607593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2007 Jan 15;96(1):104-9</RefSource>                <PMID Version="1">17213826</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Oncol. 2016 Mar 29;6:69</RefSource>                <PMID Version="1">27066453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 Feb 1;109(3):455-64</RefSource>                <PMID Version="1">17200963</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Clin Exp Pathol. 2014 Mar 15;7(4):1337-47</RefSource>                <PMID Version="1">24817930</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2016 Feb;98:242-53</RefSource>                <PMID Version="1">26616525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2003 Oct 1;66(7):1207-18</RefSource>                <PMID Version="1">14505800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Exp Metastasis. 2018 Apr;35(4):309-318</RefSource>                <PMID Version="1">29799080</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Metastasis Rev. 2014 Sep;33(2-3):823-32</RefSource>                <PMID Version="1">24984804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Pharmacol Sci. 2013 Dec;34(12):656-66</RefSource>                <PMID Version="1">24210882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2017 Jul 21;18(7):null</RefSource>                <PMID Version="1">28754000</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Oncol. 2006 Oct;29(4):1025-33</RefSource>                <PMID Version="1">16964400</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2011 Aug 11;11(9):671-7</RefSource>                <PMID Version="1">21833026</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2003 Oct 1;66(7):1219-29</RefSource>                <PMID Version="1">14505801</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Med (Berl). 2017 Dec;95(12):1341-1353</RefSource>                <PMID Version="1">28929255</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000071231" MajorTopicYN="N">Carbonic Anhydrase IX</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003606" MajorTopicYN="N">Dacarbazine</DescriptorName>                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045325" MajorTopicYN="N">HCT116 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CAIX inhibitor</Keyword>            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">SLC-0111</Keyword>            <Keyword MajorTopicYN="N">combined therapy</Keyword>            <Keyword MajorTopicYN="N">drug resistance</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30362384</ArticleId>            <ArticleId IdType="doi">10.1080/14756366.2018.1532419</ArticleId>            <ArticleId IdType="pmc">PMC6211231</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>